Related Experiment Video
Updated: Mar 30, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
23.5K
N2 extenuates experimental ischemic stroke through platelet aggregation inhibition
Lijian Yang1, Xi Chen1, Siqi Wang1
1State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing 210009, PR China.
Thrombosis Research
|November 11, 2015
Summary
N2, a potential drug for cerebral ischemia, protects against stroke by inhibiting thromboxane A2 (TXA2) formation and platelet aggregation. This compound improves neurological function and reduces brain damage with fewer bleeding risks than Clopidogrel.
Area of Science:
- Neuroscience
- Pharmacology
- Cardiovascular Research
Background:
- Thromboxane A2 (TXA2) exacerbates ischemic stroke by inducing platelet aggregation and thrombosis, leading to brain damage.
- Targeting the TXA2 pathway presents a therapeutic strategy for treating cerebral ischemia.
Purpose of the Study:
- To evaluate the neuroprotective effects of N2 (4-(2-(1H-imidazol-1-yl) ethoxy)-3-methoxybenzoic acid) in a rat model of focal cerebral ischemia and reperfusion injury.
- To determine if N2's protective effects are mediated by the inhibition of platelet aggregation.
Main Methods:
- A middle cerebral artery occlusion/reperfusion (MCAO/R) rat model was employed.
- Neurobehavioral tests (neurological deficit score, Morris water maze, postural reflex, limb-use asymmetry), infarct volume, and brain water content were assessed.
- Platelet aggregation was induced by U46619 or adenosine diphosphate (ADP) to evaluate N2's inhibitory effects.
Main Results:
- N2 treatment significantly improved motor function, learning, and memory in MCAO/R rats.
- N2 reduced infarct volume and brain water content.
- N2 inhibited platelet aggregation induced by both U46619 and ADP, suppressed TXA2 formation, and promoted prostacyclin (PGI2) production.
Conclusions:
- N2 demonstrates significant neuroprotective effects against focal cerebral ischemia and reperfusion injury.
- N2 exerts its protective action by inhibiting TXA2 formation and subsequent platelet aggregation and thrombosis.
- N2 offers a promising therapeutic agent for cerebral ischemia with a potentially better safety profile regarding bleeding complications compared to Clopidogrel.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:22Formation of the Platelet Plug
10.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.7K